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Abstract: Neurotoxicity has been linked with exposure to a number of common drugs 46 
and chemicals, yet efficient, accurate, and minimally-invasive methods to detect it are 47 
lacking. Fluid-based biomarkers such as those found in serum, plasma, urine, and 48 
cerebrospinal fluid (CSF) have great potential due to the relative ease of sampling but at 49 
present, data on their expression and translation are lacking or inconsistent. In this pilot 50 
study using a trimethyl tin (TMT) rat model of central nervous system (CNS) toxicity, we 51 
have applied state-of-the-art assessment techniques to identify potential individual 52 
biomarkers and patterns of biomarkers in serum, plasma, urine or cerebral spinal fluid 53 
that may be indicative of nerve cell damage and degeneration. Overall changes in 54 
metabolites and microRNAs were observed in biological fluids that were associated with 55 
neurotoxic damage induced by TMT. Behavioral changes and magnetic resonance 56 
imaging (MRI) T2 relaxation and ventricle volume changes served to identify animals 57 
that responded to the adverse effects of TMT. 58 
 59 
Impact Statement: These data will help design follow-on studies with other known 60 
neurotoxicants to be used to assess the broad applicabilty of the present findings. 61 
Together this approach represents an effort to begin to develop and qualify a set of 62 
translational biochemical markers of neurotoxicity that will be readily accessible in 63 
humans. Such biomarkers could prove invaluable for drug development research ranging 64 
from preclinical studies to clinical trials and may prove to assist with monitoring of the 65 
severity and life cycle of brain lesions. 66 
 67 
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Introduction: Neurotoxic effects resulting from drug and other chemical exposures pose 68 
significant public health problems.  For example, in the drug development community 69 
neurotoxicity accounts for 25% of the adverse effects seen during clinical trials (1).  70 
Environmental toxicants such as mercury, manganese, pesticides, together with 71 
contaminants in designer drugs of abuse such as 1-methyl-4-phenyl-1,2,3,6-72 
tetrahydropyridine (MPTP) and a growing inventory of industrial chemicals have been 73 
linked to neurological damage and neurodegenerative disease (2).  Understanding the 74 
long-term cognitive deficits and related biochemical derangements seen after exposure to 75 
general anesthetics (3), the proinflammatory cytokine-mediated neurotoxicity that occurs 76 
with some chemotherapies (4), the neurotoxicity induced by antiretroviral agents (5) and 77 
the neurotoxicity associated with general drug development efforts would benefit greatly 78 
from the use of a readily available fluidic biomarker(s) of neurotoxicity. Traditionally, 79 
neurotoxicity has been assessed preclinically using composite data sets including 80 
functional assessments and traditional histopathological examinations.  There are, 81 
however, many shortcomings with this approach that are evidenced by the high 82 
percentage of clinical trial failures attributable to adverse effects on the nervous system 83 
which were not identified in pre-clinical investigations.  One of the major problems is 84 
that the relevant observations are typically made over a very limited time course. 85 
Histopathologic analyses often suffer from inadequate spatial sampling and are invasive 86 
which can lead to statistical challenges and lack of longitudinal measurements (6). 87 
Functional metrics may be masked by reserve capacity, large variability, or lack of 88 
connection to underlying pathology (6).    89 
 90 
 5 
The International Life Sciences Institute (ILSI) – Health and Environmental Sciences 91 
Institute (HESI), a non-profit, science-driven organization developed a plan to identify 92 
biomarkers associated with the onset, severity, and progression of neurotoxic insult (2).  93 
The prioritization of this work was an acknowledgment that neurotoxicity poses a 94 
significant challenge that can benefit from a “big science”, collaborative approach to 95 
search for detectable biomarkers.  An expanding scientific literature is providing 96 
evidence that highlights the potential utility of fluid-based biomarkers of neurotoxicity (7, 97 
8). Similarly, neuroimaging approaches also present significant advantages for 98 
identifying potential biomarkers of neurotoxicity because they are less invasive than 99 
other procedures and, like biofluids, provide the opportunity to assess subjects repeatedly 100 
over time (9, 10).  For this pilot study, a diverse group of experts (part of the ILSI-HESI 101 
Committee on Translational Biomarkers of Neurotoxicity) reviewed existing methods 102 
and approaches and assessed the challenges and opportunities for identifying novel 103 
biomarkers associated with neurotoxicity.  The group identified fluidic biomarkers to be 104 
assessed alongside MRI endpoints with the intent to link them to traditional behavioral 105 
endpoints (2). In the present in vivo study, the prototypical neurotoxicant TMT was used 106 
in the rat as a denervation tool to generate significant CNS insult.  The selection of TMT 107 
was based on previous extensive dose and time course analyses of neurotoxicological 108 
biomarkers from studies in which the hippocampus was the focus because its damage is 109 
easily visible using Nissl stain (11, 12). Subsequently, a search for biomarkers that may 110 
be related to neurotoxicity in biological fluids was undertaken. The primary fluidic 111 
biomarkers identified included brain-abundant microRNAs (miRNAs) and a group of 112 
biomolecules representing changes in the metabolome. Continuing analyses are underway 113 
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to further mine the data to clarify the correlations between members of specific families 114 
of circulating biomarkers with histopathological endpoints of neurotoxicity that served as 115 
the phenotypic anchor for all observations. It is hoped that further validation of the 116 
current findings will lead to a formal process of biomarker qualification according to 117 
Food and Drug Administration (FDA) guidance (13) with the goal of increasing the 118 
likelihood that the identified biomarkers will be broadly employed. 119 
 120 
Materials and Methods:  Adult male Sprague Dawley rats (Taconic, Inc.,) were 121 
allocated to groups (n=12 per group per sacrifice time).  All procedures with animals 122 
were carried out according to the National Institutes of Health Guide for the Care and 123 
Use of Laboratory Animals. The animal protocol was approved by the National Center 124 
for Toxicological Research (NCTR)/FDA Institutional Animal Care and Use Committee. 125 
To monitor overt behavioral aspects of TMT effects, the locomotor activity of each 126 
animal was assessed during a 30-minute session prior to the terminal MRI and sacrifice. 127 
Baseline MRIs were obtained from all animals prior to TMT (one i.p. injection of 7 128 
mg/kg) or vehicle (saline) exposure.  Behavioral observations, and MRI scans and tissue 129 
samples were obtained at 2 (n=11/12 for TMT), 6 (n=10/12 for TMT), 10 (n=6/12 for 130 
TMT), or 14 (n=5/12 TMT) days post-treatment.  The n for control groups at all time 131 
points was 12 and all controls survived throughout the experiment except on post-132 
treatment day 6 (n=11) when one animal succumbed to anesthesia during MRI imaging. 133 
Tissue samples were collected at each time point from isoflurane anesthetized animals 134 
and included brain, plasma, serum, CSF and urine.  Samples were kept frozen at -80°C 135 
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until analysis with the specific goal of identifying key biomolecules associated with the 136 
expression of frank neurotoxicity. 137 
 138 
Locomotor activity was measured using open field apparatus as previously described 139 
(14).  Each rat was placed into a Plexiglas chamber for 30 minutes the morning of 140 
sacrifice (i.e., 2, 6, 10, and 14 days post-treatment).  Horizontal and vertical (rearing) 141 
activities were automatically recorded via a 16x16 array of photobeams (PAS-Open 142 
Field, San Diego Instruments, San Diego, CA) interfaced with a computer.  Endpoints 143 
included total horizontal activity (sum of lower beam breaks/session) and total vertical 144 
activity (sum of upper beam breaks/session). 145 
 146 
Targeted metabolomic analyses of cerebrospinal fluid (CSF), plasma, serum, and urine 147 
samples were conducted at the National Health and Environmental Effects Research 148 
Laboratory (NHEERL, Research Triangle Park, North Carolina) using an AbsoluteIDQ™ 149 
p180 kit from Biocrates Life Sciences (Innsbruck, Austria) which generates a mass 150 
spectrometry (MS)-based analysis of up to 186 metabolites of different classes 151 
(acylcarnitines, amino acids, hexoses, biogenic amines, glycerophospholipids, and 152 
sphingolipids). Analyses were performed according to kit instructions using an AB Sciex 153 
(Framingham, MA) 4000 Qtrap linear ion trap mass spectrometer. Samples (10 - 30 μL) 154 
were derivatized and extracted in 96-well plates (15). To obtain adequate sample volumes 155 
for the metabolome analyses, 2-4 CSF samples from the same sacrifice group were 156 
combined. This resulted in three samples per group at each sacrifice time. Samples were 157 
analyzed using one method (FIA/MS/MS) for lipids and hexoses and using a second 158 
 8 
method (LC/MS/MS) for amino acids and biogenic amines. Analytes were quantitated 159 
using multiple reaction monitoring transitions and internal standards. Raw data were 160 
reviewed and processed using AB Sciex Analyst (version 1.5.2) software.  Data were 161 
loaded into Biocrates MetIDQ (Boron version) software for plate QC validation. Analyte 162 
levels were compared to controls using Welch’s unequal variance t-test. Only analytes 163 
that were significantly (p<0.05) different from concurrent controls are reported. The log2 164 
fold change (treated/control mean) was calculated and graphed for the significantly 165 
altered analytes. 166 
 167 
For the miRNA analyses, quantitative polymerase chain reactions (qPCR) were 168 
performed on 78 CSF samples and 79 serum samples. 15 µl of CSF and 50 µl of serum 169 
were subjected to total RNA isolation using the miRNeasy TM kit from Qiagen (217004, 170 
Valencia CA).  All samples of a lower volume were brought up to 50 µl with water and 5 171 
µl of 200 nM cel-mIR-55 were spiked into 50 µl of CSF and serum after addition of 172 
Qiazol. RNAs were eluted in 80 µl of 95oC H2O and reverse transcription was executed 173 
using the miRCURY LNA miRNA Universal cDNA Synthesis Kit (203301, Exiqon).  A 174 
reverse transcription dilution series was employed to assess the impact of carryover PCR 175 
inhibition from the primary sample matrix.  For this test, primary total RNA isolates from 176 
a select set of serum samples were diluted 1:2, 1:4 and 1:10 and then assayed against the 177 
cel-miR-55 spike in control; the resulting PCR curves were assessed for increased 178 
sensitivity vs dilution. A 1:4 dilution of primary RNA from both plasma and serum 179 
proved optimal for mitigating PCR inhibition while preserving target sensitivity.  Five µl 180 
of the extracted RNAs, diluted 1:4, were then used in 20 µl reverse transcriptase (RT) 181 
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reactions.  A no template control (NTC) and two -RT controls were also included. Pre-182 
amplification for CSF and serum sample analysis was necessary due to both the limited 183 
volume of available sample and limited target concentration. CSF and serum samples 184 
were pre-amplified following the Exiqon miRNA Pre-Amp protocol: 2.5 µl of RT 185 
product were used for each sample type for a total reaction volume of 25 µl. Samples 186 
were diluted 1:20 immediately prior to qPCR in a 96-deep well plate by combining 25 µl 187 
of RT product and 475 µl of water.  Exiqon miRCURY LNA assays and ExiLENT 188 
SYBR Green Master Mix (203421, Exiqon) were utilized for PCR.  Four µl of cDNA 189 
was used for a total reaction volume of 20 µl.  Data were collected on a 7900HT 190 
sequence detection system (4351405, Life Technologies) and miRNA levels were 191 
compared to controls using Welch’s unequal variance t-test. Only those that were 192 
significantly (p<0.05) different from concurrent controls are reported. 193 
 194 
For the MRI scans, rats underwent imaging before TMT/vehicle exposure and on days 2, 195 
6, 10 or 14 after exposure. MRI was performed using a Bruker BioSpec 7T/30 system 196 
employing a bird-cage transmit and a 4-channel phased array rat brain-optimized receive 197 
coil (16).  Animals were anesthetized using isoflurane general anesthesia (3% induction, 198 
1-2% maintenance in 1 L/min oxygen) and body temperature was maintained at 37.0 ± 199 
0.5°C for the duration (~45 minutes). The MRI protocol consisted of anatomical scout 200 
imaging and T2 mapping. Whole brain T2 relaxation mapping was performed using a 201 
multi-echo, spin echo sequence (FOV=3.84×3.84×2.4 cm, matrix 192×192×24, 16 202 
echoes with 15 ms spacing, TR = 6 s, NA = 1). MRI T2 maps were produced from 203 
original multi-echo images using pixel-by-pixel simple exponential fitting (9) T2 maps 204 
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were skull-stripped and the number of voxels with values higher than 120 ms in manually 205 
segmented lateral ventricle areas was calculated, which represented the lateral ventricle 206 
volume in the brain as T2 of CSF is much higher than that of the brain parenchyma. 207 
Statistical analysis of ventricular volume changes was performed using a paired t-test.  208 
 209 
Results: 210 
 211 
Profiles of 29 brain-enriched miRNAs were obtained to determine whether brain-212 
enriched miRNAs observable in CSF and serum showed toxicity-related changes. Large 213 
changes in a variety of miRNAs were observed in the CSF: a ~3.5-fold increase was seen 214 
in the expression of miR-218a-5p at day 14, which typically has its largest expression in 215 
the hippocampus (Fig. 1A).  Additionally in the CSF, miR-9a-3p and 5p showed 216 
significant alterations at days 6 and 10 and 2 and 14, respectively (Fig. 1B, 1C). In serum, 217 
miRNAs 125b-5p, 138-5p and 221-3p showed small increases at day 6, however, a 218 
decrease was seen on days 2 and 10 for 221-3p and day 10 for 138-5p (Fig. 1D, E, F).   219 
 220 
Metabolite changes were observed in CSF, plasma and urine. Metabolite classes included 221 
acylcarnitines, amino acids, biogenic amines, hexoses, phosphatidylcholines, lyso-222 
phosphatidylcholines, and sphingomyelins. In CSF, increases in acylcarnitines, 223 
phosphatidylcholines, biogenic amines and sphingolipids at 2 and 6 days were noted and 224 
increases in amino acids were observed at all time points after treatment (Fig. 2A). In 225 
plasma, there were increased levels of acylcarnitines, phosphatidylcholines, amino acids, 226 
and sphingolipids at 2 and 6 days (Fig. 2B). Increased levels of acylcarnitines in urine at 227 
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2 and 6 days (Fig. 2C) were very similar to the changes noted in CSF and plasma. Very 228 
few significant increases in acylcarnitines were observed in the serum metabolome (Fig. 229 
2D). 230 
 231 
For locomotor activity, ANOVAs indicated significant interactions of treatment by 232 
number of days post-treatment for total horizontal activity and total vertical activity.  233 
Relative to the control group, the TMT-treated group exhibited significantly decreased 234 
horizontal activity at 6 days post-treatment, but increased activity at 10 days post-235 
treatment (Fig. 3).  236 
 237 
MRI showed significant increases in CSF volumes in the lateral ventricles of TMT-238 
treated rats without significant edema, as only few animals showed detectable increases 239 
of T2 relaxation values in the hippocampus (Fig. 4). 240 
 241 
Discussion: Our findings suggest that TMT induced significant changes in energy 242 
metabolism and damage to mitochondria and membranes, presumably in the CNS as no 243 
or minimal toxicities were observed in any other tissue examined (liver, kidney, thymus, 244 
adrenal and sciatic nerve, data not shown).  Biological markers of these effects were 245 
reflected in bodily fluids as well as brain tissue. It remains to be determined if plasma and 246 
urine markers identified here will consistently mirror CSF markers of frank CNS 247 
neuropathology (cell death).  If this is the case then they may serve as useful, readily 248 
accessible surrogates of neurotoxicity.  249 
 250 
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Identifying biomarkers relevant to neurotoxicity is vital for developing tools to monitor 251 
adverse nervous system events. Appropriate molecular and physiological biomarkers 252 
should serve as predictive indicators of neurotoxicity.  The present results demonstrate 253 
that a major neurotoxic event, exposure to TMT, can result in significant alterations in the 254 
metabolome and miRNA expression, all of which likely play roles in neuronal function. 255 
Such fluidic changes were accompanied by typical TMT-induced behavioral changes and 256 
MRI signals.   257 
 258 
miRNAs are valuable biomolecules because of their stability and, thus, detectability. 259 
Their non-antibody based detection and their stability in bodily fluids facilitates their 260 
translational utility (17-19) and there are several sensitive detection methods available for 261 
the identification of pathological miRNAs (20). A recent study showed that different 262 
miRNA expression patterns are associated with specific MRI measures that are 263 
characteristic of the different stages and severity of multiple sclerosis and, thus, can serve 264 
as surrogate markers of disease progression (21). In the present study, hippocampus-265 
specific miR-218a-5p was significantly increased in CSF after TMT exposure. miR-218a-266 
5p is enriched in the brain with its highest expression occurring in the hippocampus, 267 
cortex and cerebellum.  There is some expression in the duodenum and minimal 268 
expression in the kidney (22). A recent study has shown that CSF levels of miR-218 269 
correlated with the motor neuron loss in models of amyotrophic lateral sclerosis (ALS) 270 
suggesting that it may be a clinically useful marker of ALS progression (23). Our 271 
observation of miR-218a-5p increases in CSF after TMT-induced neurotoxicity supports 272 
the notion that it is a biomarker for CNS neurotoxicity. The miR-9 family is highly 273 
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expressed in both the developing and adult vertebrate brain and participates in neuronal 274 
progenitor maintenance, neurogenesis and neuron differentiation (24). A recent study has 275 
shown that miR-9-5p/3p are integral to the regulation of brain development and their 276 
derangement has been implicated in several neurological disorders: it has been suggested 277 
that miR-9-3p regulates synaptic plasticity and memory (25). In the present study, miR-278 
9a-3p and -5 were elevated in CSF at varying times after TMT exposure. In addition, 279 
significant changes were observed in a few miRNAs in serum after TMT-exposure: the 280 
relevance of those miRNAs to neuronal health has yet to be established. 281 
 282 
The metabolomic analysis presented here included a large list of metabolites representing 283 
many physiological processes. Such a wide range of metabolites is likely to represent the 284 
overall metabolic profile of the whole animal. It is important to note that pathology was 285 
not observed in the periphery in organs included the liver, kidney, thymus, adrenal and 286 
sciatic nerve. While not definitive, these finding suggest that that observed changes in 287 
metabolic profiles reflect responses to CNS toxicity. It is important to note that the results 288 
of the metabolomic analysis are presented in terms of “classes” of metabolites to assist 289 
with interpreting which large scale processes may have been altered by TMT. However, 290 
findings for individual metabolites (some of which could be generated by multiple 291 
pathways) are available for analysis. Collectively, the observed metabolomic changes 292 
suggest alterations in energy metabolism and mitochondrial and membrane damage, 293 
presumably in the central nervous system. 294 
 295 
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When quantifying biomarkers such as these metabolomic measures, interpretation of 296 
observed changes should be made after considerations of criteria such as those described 297 
in the modified Bradford-Hill criteria (26, 27). These criteria include: 1) are the changes 298 
dose-related? (not addressed in the present study); 2) do the changes correlate with the 299 
time-course of toxicity? (yes in this study, changes in the metabolome were observed that 300 
correlated with the time-course of other measures of neurotoxicity); 3) if the toxicity is 301 
blocked, are the metabolomic changes reversible? (this was not addressed in the current 302 
study); and 4) are the changes biologically plausible – are the changes in the metabolome 303 
consistent with what is known about the mechanism of toxicity? (at least partially yes in 304 
the present study, the metabolic changes are consistent with degeneration of cells, 305 
membranes, and altered mitochondrial respiration). Thus, the changes in the fluid 306 
metabolome reported here are consistent with TMT-induced neurotoxicity within the 307 
framework of the current study. Clearly, additional work is necessary to more directly 308 
link these alterations in metabolomic markers to neurotoxicity and to identify possible 309 
contributions from other tissue/cell types. 310 
 311 
The observation that TMT-induced time-dependent changes in the levels of acylcarnitines 312 
in CSF, plasma, serum and urine clearly shows that they are correlated with TMT-313 
induced changes in brain and that they may represent early signals of CNS damage.  314 
Brain acylcarnitines play major roles in the maintenance of mitochondrial function and 315 
cholinergic transmission (28) and neuronal acylcarnitines provide antioxidant support and 316 
contribute to membrane integrity via their role in lipid biosynthesis (29). The increase in 317 
CSF acylcarnitine levels at the earlier time points after TMT administration might 318 
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suggest an attempt to boost cellular defense mechanisms that subsequently drop as cells 319 
die at later time points. The pattern of acylcarnitine levels observed in the CSF is also 320 
reflected in plasma and urine, thereby suggesting that fluid levels of acylcarnitines are 321 
correlated with the neurotoxic response to TMT. 322 
 323 
Changes in brain levels of amino acids noted in the present study suggest changes in 324 
various physiological functions including energy production, neurotransmitter regulation, 325 
and cellular architecture (30).  In the present study, there was a persistent increase in 326 
amino acid levels in CSF over the 14 days of observation but a time-dependent decline in 327 
serum, plasma and urine levels.  This observation might be indicative of transport of 328 
amino acids from the periphery into the CNS or an alteration of amino acid metabolism 329 
in the CNS itself. 330 
  331 
Phospholipids and sphingolipids form integral components of cellular membranes and 332 
lipoproteins (31, 32) and neuronal membrane integrity is critical for inter- and intra-333 
neuronal communication. Changes in these membrane constituents likely accompany 334 
neurodegenerative changes (33), which have been reported as early as 2 days after 335 
treatment with TMT (11). Thus, it is important to note that these changes in the 336 
metabolome were in concordance with some of the earliest reported neuronal toxicity 337 
produced by TMT. 338 
 339 
MRI techniques represent significant advances in the diagnosis and monitoring of 340 
neurological disease (34, 35). Imaging techniques, especially MRI, provide tools for 341 
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differentiating among heterogeneous pathologic processes:  they can be used to evaluate 342 
axonal and neuronal loss and progressive neurodegenerative processes and to link 343 
physical brain damage with cognitive impairment (36, 37). In the present studies, the 344 
neurotoxic damage induced by TMT was employed as a phenotypic anchor to which 345 
fluidic biomarkers and alterations in MRI signals can be tied: TMT-induced neurotoxicity 346 
that resulted in alterations in fluidic metabolomic markers and brain-enriched miRNAs 347 
also produced significant increase in lateral ventricular volume in all impaired rats 348 
without the development of any edema; T2 relaxation measures were also affected in the 349 
hippocampus. Enlarged ventricles observed after TMT exposure have also been reported 350 
previously but they were described in terms of decreases in the volume of the neuropil as 351 
evident morphologically by loss of weight of the hippocampus after TMT exposure 352 
(12).  Increases in ventricular volumes that might represent a loss of hippocampal 353 
neuropil may be independent of blood-brain-barrier (BBB) damage, as TMT has not been 354 
reported to induce significant BBB damage around the onset of neuropathology during 355 
TMT-induced neurotoxic damage (38). 356 
 357 
Although the present studies are preliminary, they provide solid platforms from which to 358 
search for minimally-invasive neuronal and bio-fluid based biomarkers of neurotoxic 359 
damage after CNS insult. It is hoped that future studies based on these current findings 360 
will reveal specific circulating biomarkers related to the extent of neurotoxic damage. 361 
Such biomarkers would be beneficial during drug development, injury assessments and 362 
diagnoses, and therapeutic monitoring.  363 
 364 
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Figure Legends: 526 
 527 
Figure 1: miRNA profiles in CSF (A-C) and serum (D-F) of adult male rats 2, 6, 10 and 528 
14 days after a single dose of TMT. miRNA levels were compared to controls using 529 
Welch’s unequal variance t-test. Only those that were significantly (p<0.05, *) different 530 
from concurrent controls are reported. 531 
 532 
Figure 2: Metabolite levels in CSF (A), plasma (B), urine (C) and serum (D) of adult 533 
male rats 2, 6, 10 and 14 days after a single dose of TMT. Analyte levels were compared 534 
to controls using Welch’s unequal variance t-test. Only analytes that were significantly 535 
(p<0.05) different from concurrent controls on each day are reported. The log2 fold 536 
change (treated/control mean) was calculated and graphed for the significantly altered 537 
analytes (a = number of metabolites significantly altered; b = number of metabolites 538 
detected within the range of quantitation, all sugars were grouped as a singular hexose 539 
metabolite). 540 
 541 
Figure 3: Locomotor activity as measured by photo-beam breaks of adult male rats 2, 6, 542 
10 and 14 days after a single dose of TMT. Post-hoc comparisons of the significant 543 
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interaction of treatment (saline vs. TMT) and days post-treatment indicated that the saline 544 
and TMT groups differed significantly at day 6 only.   545 
 546 
Figure 4: An example of a T2 relaxation map (top panel, single slice out of 24) of one 547 
TMT-treated animal (at baseline and after TMT treatment) shows both a T2 increase in 548 
the dorsal hippocampus (small arrow) as well as an increase in the volume of the lateral 549 
ventricle (large arrow). The bar graph (bottom panel) shows averaged changes in the 550 
lateral ventricle volumes in rats after 2, 6, 10, and 14 days after TMT treatment. P value 551 
represents the statistical significance of difference between control and TMT groups. 552 
Data are Means ± S.E.Ms. 553 
